A prevention strategy developed by Canadian researchers can reduce the risk of the most common and deadly form of ovarian cancer by nearly 80 per cent. The strategy, known as opportunistic salpingectomy (OS), involves proactively removing a person’s fallopian tubes when they are already undergoing a routine gynaecological surgery such as hysterectomy or tubal ligation. The study analyzed population-based health data for more than 85,000 people who underwent gynaecological surgeries in B.C. between 2008 and 2020. The researchers compared rates of serous ovarian cancer between those who had OS and those who had similar surgeries but did not undergo the procedure. Overall, people who had OS were 78 per cent less likely to develop serous ovarian cancer.
 

OYE Therapeutics has been authorized to initiate clinical development of its OYE-101 caffeine injection after the U.S. FDA cleared its Investigational New Drug applications. OYE-101 is a novel intravenous formulation that reverses the effects of, or accelerates emergence from, general anesthesia and deep sedation in adults.

Although scientists have known some of the factors that raise a person’s risk of Parkinson's disease, the question remains of why some people with genetic risk factors develop the disease while others never do. A team at Baylor College of Medicine, the Duncan Neurological Research Institute (Duncan NRI) at Texas Children’s Hospital and collaborating institutions found in the laboratory fruit fly that it takes two mutant genes to drive neurodegeneration. The findings can lead to novel interventions for this devastating condition.

CHEST Critical Care, part of the CHEST journal portfolio, receives approval for indexation with Web of Science Core Collection and will receive a 2025 Impact Factor.